Literature DB >> 28477334

Serology of Streptococcus gallolyticus subspecies gallolyticus and its association with colorectal cancer and precursors.

Julia Butt1, Simone Werner2, Martina Willhauck-Fleckenstein1, Angelika Michel1, Tim Waterboer1, Inka Zörnig3, Annemarie Boleij4, Shaynoor Dramsi5, Hermann Brenner2, Michael Pawlita1.   

Abstract

Streptococcus gallolyticus subspecies gallolyticus (SGG) is potentially associated with colorectal cancer (CRC) and its precursors. A previous case-control study measured antibody responses to SGG pilus proteins Gallo2178 and Gallo2179 and identified significant associations with a small fraction of CRC cases. We aimed at replicating and expanding these findings in an independent study including additional SGG antigens and explored the association with precancerous lesions. We applied multiplex serology to measure antibodies to eleven SGG proteins in serum samples of a screening colonoscopy trial (BliTz study) including participants diagnosed with either non-advanced adenoma (NAA, n = 30), advanced adenoma (AA, n = 100), CRC (n = 50) or controls (n = 228). In addition, we analyzed CRC samples (n = 318) from patients recruited in a clinical setting (DACHSplus study). The association of antibody responses to SGG pilus proteins Gallo2178 and Gallo2179 with CRC was replicated with 4% positive DACHSplus cases compared to 0% positive BliTz controls. Positivity to two or more proteins of a newly defined panel of six SGG markers was significantly associated with CRC in the DACHSplus study (OR: 1.81, 95% CI: 1.07-3.06). Odds for CRC, AA and NAA in the BliTz study were also increased with antibody responses to SGG, and the association was significant for NAA (OR: 2.98, 95% CI: 1.18-7.57). Antibody responses to SGG are associated with CRC and its precursors. The newly identified SGG six-marker panel and associations found with precancerous lesions should be further explored.
© 2017 UICC.

Entities:  

Keywords:  adenoma; antibodies; bacterial infection; case-control study; colorectal cancer

Mesh:

Substances:

Year:  2017        PMID: 28477334     DOI: 10.1002/ijc.30765

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Effect of gut microbiota in the colorectal cancer and potential target therapy.

Authors:  Junchuan Li; Yuzhou Zhu; Lie Yang; Ziqiang Wang
Journal:  Discov Oncol       Date:  2022-06-24

2.  Antibody Responses to Streptococcus Gallolyticus Subspecies Gallolyticus Proteins in a Large Prospective Colorectal Cancer Cohort Consortium.

Authors:  Julia Butt; William J Blot; Lauren R Teras; Kala Visvanathan; Loïc Le Marchand; Christopher A Haiman; Yu Chen; Ying Bao; Howard D Sesso; Sylvia Wassertheil-Smoller; Gloria Y Ho; Lesley F Tinker; Richard M Peek; John D Potter; Timothy L Cover; Laura H Hendrix; Li-Ching Huang; Tim Waterboer; Michael Pawlita; Meira Epplein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

3.  Validation of Multiplex Serology detecting human herpesviruses 1-5.

Authors:  Nicole Brenner; Alexander J Mentzer; Julia Butt; Angelika Michel; Kristina Prager; Johannes Brozy; Benedikt Weißbrich; Allison E Aiello; Helen C S Meier; Judy Breuer; Rachael Almond; Naomi Allen; Michael Pawlita; Tim Waterboer
Journal:  PLoS One       Date:  2018-12-27       Impact factor: 3.240

4.  Antibody responses to flagellin C and Streptococcus gallolyticus pilus proteins in colorectal cancer.

Authors:  Julia Butt; Nerea Fernández de Larrea; Harold Tjalsma; Rian Roelofs; Ikuko Kato; Vicente Martín; Beatriz Pérez-Gómez; Victor Moreno; Trinidad Dierssen-Sotos; Jesús Castilla; Guillermo Fernández-Tardón; Pilar Amiano; Dolores Salas; Juan Alguacil; José Juan Jiménez-Moleón; José María Huerta; Silvia de Sanjosé; Rosa Del Campo; Manolis Kogevinas; Marina Pollán; Michael Pawlita; Tim Waterboer; Annemarie Boleij; Nuria Aragonés
Journal:  Sci Rep       Date:  2019-07-26       Impact factor: 4.379

5.  Gut Microbiota and Depressive Symptoms at the End of CRT for Rectal Cancer: A Cross-Sectional Pilot Study.

Authors:  Velda J Gonzalez-Mercado; Jean Lim; Leorey N Saligan; Nicole Perez; Carmen Rodriguez; Raul Bernabe; Samia Ozorio; Elsa Pedro; Farrah Sepehri; Brad Aouizerat
Journal:  Depress Res Treat       Date:  2021-12-29

6.  Fusobacterium nucleatum predicts a high risk of metastasis for esophageal squamous cell carcinoma.

Authors:  Zhen Li; Chao Shi; Jiawen Zheng; Yongjun Guo; Taibing Fan; Huan Zhao; Dongdong Jian; Xiaolei Cheng; Hao Tang; Jie Ma
Journal:  BMC Microbiol       Date:  2021-10-30       Impact factor: 3.605

7.  Streptococcus gallolyticus Increases Expression and Activity of Aryl Hydrocarbon Receptor-Dependent CYP1 Biotransformation Capacity in Colorectal Epithelial Cells.

Authors:  Rahwa Taddese; Rian Roelofs; Derk Draper; Xinqun Wu; Shaoguang Wu; Dorine W Swinkels; Harold Tjalsma; Annemarie Boleij
Journal:  Front Cell Infect Microbiol       Date:  2021-10-27       Impact factor: 5.293

Review 8.  The Road to Infection: Host-Microbe Interactions Defining the Pathogenicity of Streptococcus bovis/Streptococcus equinus Complex Members.

Authors:  Christoph Jans; Annemarie Boleij
Journal:  Front Microbiol       Date:  2018-04-10       Impact factor: 5.640

9.  Association of Combined Sero-Positivity to Helicobacter pylori and Streptococcus gallolyticus with Risk of Colorectal Cancer.

Authors:  Meira Epplein; Loïc Le Marchand; Timothy L Cover; Mingyang Song; William J Blot; Richard M Peek; Lauren R Teras; Kala Visvanathan; Yu Chen; Howard D Sesso; Anne Zeleniuch-Jacquotte; Sonja I Berndt; John D Potter; Marc D Ryser; Christopher A Haiman; Sylvia Wassertheil-Smoller; Lesley F Tinker; Tim Waterboer; Julia Butt
Journal:  Microorganisms       Date:  2020-10-30

Review 10.  Bacterial and Parasitic Pathogens as Risk Factors for Cancers in the Gastrointestinal Tract: A Review of Current Epidemiological Knowledge.

Authors:  Janneke W Duijster; Eelco Franz; Jacques Neefjes; Lapo Mughini-Gras
Journal:  Front Microbiol       Date:  2021-12-08       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.